Etoricoxib, letrozole and trimethoprim experienced triple-digit rises in their average UK trade prices in March, according to the latest figures from WaveData.

Merck has agreed to discontinue a “predatory strategy” for the company’s Temodal (temozolomide) oncology brand in Austria that kept generics out of the market, including by supplying the brand below cost price, under commitments offered to the country’s competition watchdog.

Canada’s Valeo Pharma insists it has “worked tirelessly to ensure a robust supply of Redesca,” after completing another milestone for the company’s enoxaparin biosimilar product.

As Warwick Smith steps down after 25 years as leader of the British Generic Manufacturers Association, he talks about how far the country’s off-patent industry has come over the last quarter-century – including the acceptance of generics, the advent of biosimilars, and how freedom of pricing has helped to keep costs low while maintaining sustainable pricing – in the first part of an exclusive interview with Generics Bulletin.

With well over 3,000 off-patent medicines set for a price cut from the start of April in Belgium, local industry association Medaxes has voiced its support for government-led healthcare cost efficiencies but has warned of the risks of driving players out of the market with unsustainably low prices.

The AAM has urged the US Congress to increase biosimilar reimbursement through higher Medicare Part B add-on payments for biosimilars, based on a recent IQVIA report that has identified a correlation between Medicare payments and biosimilar adoption. The AAM has also urged the CMS to establish a shared savings program.